ALG13 variants underlie infantile-onset developmental and epileptic encephalopathy (DEE) (Timal et al., 2012; Ng et al., 2020; Alsharhan et al., 2021; Datta et al., 2021), while ALG14 gene mutants present as early lethal neurodegeneration with myasthenic and myopathic features, also known as congenital myasthenic syndrome (CMS) (Judith et al., 2013; Schorling et al., 2017; Datta et al., 2021; Katata et al., 2022). This evidence concerns the gene ALG14 and congenital myasthenic syndrome.